FR11C0027I2 - Virus de l'influenza recombinants pour vaccins et traitement genetique - Google Patents

Virus de l'influenza recombinants pour vaccins et traitement genetique

Info

Publication number
FR11C0027I2
FR11C0027I2 FR11C0027C FR11C0027C FR11C0027I2 FR 11C0027 I2 FR11C0027 I2 FR 11C0027I2 FR 11C0027 C FR11C0027 C FR 11C0027C FR 11C0027 C FR11C0027 C FR 11C0027C FR 11C0027 I2 FR11C0027 I2 FR 11C0027I2
Authority
FR
France
Prior art keywords
vaccines
influenza viruses
recombinant influenza
genetic treatment
genetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0027C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26826080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0027(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of FR11C0027I1 publication Critical patent/FR11C0027I1/fr
Application granted granted Critical
Publication of FR11C0027I2 publication Critical patent/FR11C0027I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
FR11C0027C 1999-04-06 2011-07-26 Virus de l'influenza recombinants pour vaccins et traitement genetique Active FR11C0027I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12791299P 1999-04-06 1999-04-06
US13283999P 1999-05-06 1999-05-06
PCT/US2000/009021 WO2000060050A2 (fr) 1999-04-06 2000-04-05 Virus de l'influenza recombinants pour vaccins et traitement genetique

Publications (2)

Publication Number Publication Date
FR11C0027I1 FR11C0027I1 (fr) 2011-08-26
FR11C0027I2 true FR11C0027I2 (fr) 2021-12-31

Family

ID=26826080

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0027C Active FR11C0027I2 (fr) 1999-04-06 2011-07-26 Virus de l'influenza recombinants pour vaccins et traitement genetique

Country Status (19)

Country Link
EP (4) EP1820853B1 (fr)
JP (3) JP5543048B2 (fr)
KR (1) KR100702275B1 (fr)
CN (2) CN1350578B (fr)
AT (2) ATE368729T1 (fr)
AU (1) AU4073300A (fr)
BR (1) BRPI0009580B8 (fr)
CA (2) CA2928263A1 (fr)
CY (2) CY1108520T1 (fr)
DE (6) DE60035778T2 (fr)
DK (3) DK1820853T3 (fr)
ES (3) ES2373405T3 (fr)
FR (1) FR11C0027I2 (fr)
HK (2) HK1148778A1 (fr)
IL (2) IL145702A0 (fr)
MX (1) MXPA01010082A (fr)
NL (2) NL300365I2 (fr)
PT (2) PT1185615E (fr)
WO (1) WO2000060050A2 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
EP1820853B1 (fr) * 1999-04-06 2011-09-21 Wisconsin Alumni Research Foundation Virus de la grippe recombinant pour vaccins et thérapie génétique
DK1194580T4 (da) * 1999-07-14 2011-01-03 Sinai School Medicine In-vitro rekonstitution af segmenterede negativstrengede RNA-virus
GB9916794D0 (en) * 1999-07-16 1999-09-22 Isis Innovation In vitro virus reconstitution
ATE420189T1 (de) 2000-04-28 2009-01-15 St Jude Childrens Res Hospital Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
EP1862550A1 (fr) * 2000-06-23 2007-12-05 Wyeth Holdings Corporation Ensemble de particules de virus du type de la grippe chimérique et sauvage (VLP)
JP5008244B2 (ja) 2000-06-23 2012-08-22 ワイス・ホールディングズ・コーポレイション 野性型およびキメラのインフルエンザウイルス様粒子（ｖｌｐ）のアセンブリー
US7211378B2 (en) 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
AU2003219745B8 (en) 2002-02-13 2008-10-09 Wisconsin Alumni Research Foundation Signal for packaging of influenza virus vectors
KR101229202B1 (ko) 2002-04-26 2013-02-01 메디뮨 엘엘씨 인플루엔자 바이러스의 생산을 위한 다중 플라스미드 시스템
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
ES2593082T3 (es) * 2003-05-28 2016-12-05 Wisconsin Alumni Research Foundation Virus de la gripe recombinantes a título elevado para vacunas y terapia génica
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
CA2551489C (fr) 2003-12-23 2013-09-03 Gregory Duke Systeme a plasmides multiples pour la production du virus de la grippe
FR2866031B1 (fr) * 2004-02-11 2012-10-19 David Francois Joseph Millet Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
US7504109B2 (en) 2004-05-25 2009-03-17 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
JP2008520248A (ja) 2004-11-19 2008-06-19 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション タンデム転写ユニットを有する組換えインフルエンザベクター
CN102978169A (zh) 2004-12-08 2013-03-20 米迪缪尼有限公司 生产流感疫苗组合物的方法
KR101272487B1 (ko) 2004-12-24 2013-06-07 에라스무스 유니버시티 메디컬 센터 로테르담 인플루엔자 바이러스의 구제
EP2471552B1 (fr) 2005-03-08 2015-05-06 MedImmune, LLC Virus de la grippe réassortis
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
ATE539765T1 (de) 2005-11-04 2012-01-15 Novartis Vaccines & Diagnostic Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern
WO2007052061A2 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions a tensioactif a phase aqueuse libre pour adjuver des vaccins antigrippaux sous-unitaires
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
EP1951298A1 (fr) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Vaccins influenza avec adjuvant comprenant des agents d'induction de cytokines
NZ595736A (en) 2005-12-02 2013-05-31 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
BRPI0707300B8 (pt) 2006-01-27 2021-05-25 Novartis Ag vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica
WO2007110776A1 (fr) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Stockage de vaccins antigrippaux sans refrigeration
WO2007126810A2 (fr) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation Virus de la grippe recombinants à haut titre pour vaccins
WO2007146057A2 (fr) * 2006-06-09 2007-12-21 Wisconsin Alumni Research Foundation Procédé de criblage destiné à la détermination de modulateurs de la transcription ou de la réplication virale
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2049662A4 (fr) 2006-07-21 2009-12-30 Medimmune Llc Procédés et compositions permettant d'accroître la capacité de réplication d'un virus de la grippe
CN101983069B (zh) 2006-08-09 2014-07-16 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
CA3016948A1 (fr) 2006-09-11 2008-03-20 Seqirus UK Limited Fabrication de vaccins contre le virus grippal sans utiliser d'oeufs
AU2007330494B2 (en) 2006-12-06 2014-03-13 Seqirus UK Limited Vaccines including antigen from four strains of influenza virus
US8597661B2 (en) 2007-05-04 2013-12-03 Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
EP2069484B1 (fr) 2007-06-18 2014-08-13 MedImmune, LLC Virus B de la grippe présentant des modifications du polypeptide de l'hémagglutinine
WO2008156778A2 (fr) 2007-06-18 2008-12-24 Tokiko Watanabe Virus mutants de protéine m2 de la grippe comme vaccins vivants atténués contre la grippe
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
EP2045323A1 (fr) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Constructions linéaires d'expression pour la production de particules de virus influenza
CN101497877B (zh) * 2008-01-28 2012-09-05 河北摩百生物科技有限公司 流感全病毒减活疫苗重组体、其构建方法及应用
US20110014230A1 (en) 2008-03-18 2011-01-20 Novartis Ag preparation of influenza virus vaccine antigens
RU2523587C2 (ru) 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
CA2734643A1 (fr) 2008-08-18 2010-02-25 The Kitasato Institute Antigene du virus de la grippe aviaire et procede d'immunisation de rappel pour un vaccin contre la grippe aviaire en combinaison avec un adjuvant muqueux qui est efficace par administration orale
EP2233568A1 (fr) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Nouveau procédé pour la génération de virus d'ARN
JP5642712B2 (ja) 2009-02-10 2014-12-17 ノバルティス アーゲー 少ない量のスクアレンを含むインフルエンザワクチン
AU2010212548A1 (en) 2009-02-10 2011-09-15 Novartis Ag Influenza vaccines with increased amounts of H3 antigen
CN102438651A (zh) 2009-02-10 2012-05-02 诺华有限公司 用于大流行相关毒株的流感疫苗方案
AU2010213966B2 (en) 2009-02-12 2015-01-22 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP2424565A1 (fr) 2009-04-27 2012-03-07 Novartis AG Vaccins avec adjuvants pour protéger du virus de la grippe
WO2011030218A1 (fr) 2009-09-10 2011-03-17 Novartis Ag Vaccins combinés contre les maladies des voies respiratoires
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP2576773A2 (fr) 2010-06-02 2013-04-10 Avir Green Hills Biotechnology Research Development Trade AG Procédés et virus auxiliaires pour la génération d'un virus à arn
CN102220293B (zh) * 2011-05-26 2012-12-19 中国农业科学院上海兽医研究所 犬流感重组病毒及其制备方法和应用
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
US20140302077A1 (en) 2011-09-02 2014-10-09 Westfaelische Wilhelms-Universitaet Munester Live attenuated influenza virus
WO2013057715A1 (fr) 2011-10-20 2013-04-25 Novartis Ag Vaccins avec adjuvant contre le virus grippal b pour primo-vaccination pédiatrique
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
AU2014290203B2 (en) 2013-07-15 2020-12-24 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN104450695B (zh) * 2014-11-26 2017-08-25 扬州大学 A型流感病毒基因pcr扩增引物及其快速克隆方法
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
EP3313439A2 (fr) 2015-06-26 2018-05-02 Seqirus UK Limited Vaccins contre la grippe à correspondance antigénique
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
JP6830070B2 (ja) 2015-07-07 2021-02-17 セキラス ユーケー リミテッドＳｅｑｉｒｕｓ ＵＫ Ｌｉｍｉｔｅｄ インフルエンザ効力アッセイ
EP3341018A1 (fr) * 2015-08-28 2018-07-04 Wisconsin Alumni Research Foundation Génération de virus de la grippe infectieux à partir de pseudo-particules virales (vlp)
WO2017143236A1 (fr) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Réplication améliorée du virus de la grippe b pour l'élaboration de vaccin
EP3675834A1 (fr) * 2017-08-28 2020-07-08 Wisconsin Alumini Research Foundation Nanocapsules pour l'administration de ribonucléoprotéines
CN107964035B (zh) * 2017-12-06 2020-07-24 中国科学院微生物研究所 一种用于流感病毒的有限复制型黏膜免疫疫苗
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
EP3914295A2 (fr) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe
WO2020163804A1 (fr) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Lignée cellulaire humanisée
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
WO2021041624A2 (fr) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Virus de la grippe recombinants à ha stabilisé pour réplication dans des oeufs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5658772A (en) 1989-12-22 1997-08-19 E. I. Du Pont De Nemours And Company Site-specific recombination of DNA in plant cells
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
WO1996010633A1 (fr) * 1994-09-30 1996-04-11 Aviron Virus chimere de la grippe et procede d'electroporation
EP0704533A1 (fr) * 1994-09-30 1996-04-03 Bayer Ag Virus atténué pour la vaccination, méthode pour sa fabrication et compositions pharmaceutiques le contenant
CN1200675A (zh) * 1995-10-20 1998-12-02 耶路撒冷希伯来语大学依苏姆研究开发公司 流感疫苗
US5994526A (en) * 1996-06-21 1999-11-30 Plant Genetic Systems Gene expression in plants
EP1035209A1 (fr) * 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Virus influenza recombinants stables dépourvus de virus auxiliaire
EP1820853B1 (fr) * 1999-04-06 2011-09-21 Wisconsin Alumni Research Foundation Virus de la grippe recombinant pour vaccins et thérapie génétique

Also Published As

Publication number Publication date
AU4073300A (en) 2000-10-23
NL300365I2 (nl) 2017-08-03
WO2000060050A3 (fr) 2001-01-18
PT1185615E (pt) 2007-10-04
CA2365526A1 (fr) 2000-10-12
DE60035778T2 (de) 2008-04-30
EP1185615B1 (fr) 2007-08-01
EP1820853A3 (fr) 2007-10-03
EP1820853A2 (fr) 2007-08-22
FR11C0027I1 (fr) 2011-08-26
HK1148778A1 (zh) 2011-09-16
DE122008000061I1 (de) 2009-02-12
NL300364I2 (nl) 2017-08-03
KR100702275B1 (ko) 2007-03-30
EP1185615A2 (fr) 2002-03-13
CY1112140T1 (el) 2015-11-04
CN101851636B (zh) 2015-11-25
BR0009580A (pt) 2002-01-02
JP2015119735A (ja) 2015-07-02
JP2003528570A (ja) 2003-09-30
MXPA01010082A (es) 2002-04-24
DE122008000058I1 (de) 2009-05-07
EP2910629A1 (fr) 2015-08-26
NL300365I1 (nl) 2009-01-05
EP2910629B1 (fr) 2018-09-19
KR20010113044A (ko) 2001-12-24
DK1185615T3 (da) 2007-11-05
EP2345716B1 (fr) 2015-01-14
PT1820853E (pt) 2012-01-03
DE60035778D1 (de) 2007-09-13
HK1214298A1 (zh) 2016-07-22
JP2011182797A (ja) 2011-09-22
DE122011100037I1 (de) 2012-03-22
JP5543048B2 (ja) 2014-07-09
BRPI0009580B8 (pt) 2021-05-25
CY1108520T1 (el) 2014-04-09
DK2345716T3 (en) 2015-02-09
ATE368729T1 (de) 2007-08-15
EP1820853B1 (fr) 2011-09-21
JP5775351B2 (ja) 2015-09-09
CA2365526C (fr) 2016-07-05
CA2928263A1 (fr) 2000-10-12
NL300364I1 (nl) 2009-01-05
WO2000060050A2 (fr) 2000-10-12
CN1350578B (zh) 2010-05-12
JP6224645B2 (ja) 2017-11-01
ES2533622T3 (es) 2015-04-13
CN1350578A (zh) 2002-05-22
DE122008000035I1 (de) 2009-05-20
DE122008000014I1 (de) 2011-12-01
DK1820853T3 (da) 2011-12-19
ATE525461T1 (de) 2011-10-15
BR0009580B1 (pt) 2014-11-25
EP2345716A1 (fr) 2011-07-20
ES2373405T3 (es) 2012-02-03
IL145702A0 (en) 2002-07-25
ES2290024T3 (es) 2008-02-16
CN101851636A (zh) 2010-10-06
IL145702A (en) 2010-04-15

Similar Documents

Publication Publication Date Title
FR11C0027I2 (fr) Virus de l'influenza recombinants pour vaccins et traitement genetique
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
EA200201279A1 (ru) Способы и композиции для лечения вирусного гепатита c
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
UA85536C2 (en) Viral antigens
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
BG102712A (en) Mixture of recombinant vaccinia vectors as polyenv-vaccines against hiv
ATE376825T1 (de) Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
ATE295180T1 (de) Zubereitung zur immunisierung gegen den aids- virus
ATE395078T1 (de) Impfstoff zur vorbeugung bzw. behandlung der hepatitis c
BR0310020A (pt) Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
DE60024259D1 (de) Trennung eines humanen retrovirus
DK1339737T3 (da) Immunomodulatorisk protein dannet ud fra Yaba-abetumorvirus
FI964784A (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
DE60035680D1 (de) Komplette gensequenz des esel-leukozyten-impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung
ATE189604T1 (de) Extrakte von piliostigma thonningii, deren verwendung und diese enthaltende zubereitungen
WO2002039116A3 (fr) Retrovirus isoles chez l'homme
WO2000024876A3 (fr) Nouveau retrovirus isole chez l'homme